SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Authors

  • Arif Qayyum Khan Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Hala Mansoor Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Samina Fida Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Saba Saif Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Javed Iqbal Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Siddique Combined Military Hospital Lahore Medical College and Institute of Dentistry Lahore/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i1.4339

Keywords:

Hepatitis C, Sustained virological response, Sofosbuvir, Velpatasvir

Abstract

Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of
chronic hepatitis C genotype 3.

Study Design: Prospective cohort study.

Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to
Oct 2019.

Methodology: Eighty eight consecutive patients, who were ≥18 years of age with chronic hepatitis C as confirmed by polymerase chain reaction were included in the study. Primary end point was sustained virological response at 12 week post-treatment. Patients with any of the following criteria at presentation were excluded from study: aspartate/alanine aminotransferase >10 times the upper limit of normal, total bilirubin twice the upper limit of normal, haemoglobin <8g/dL, platelet count <30,000/uL, albumin <2 g/dL and creatinine clearance of <60 mL/ min. Additional criteria for exclusion included patients who had co-infection with hepatitis B or human immune deficiency virus (HIV), significant cardiac or lung disease, porphyria, liver cirrhosis caused by non-HCV related causes or co-existent hepatocellular carcinoma.

Results: Overall sustained virological response was achieved in 82 of 84 patients (97.6%). One of the patients with genotype 3 had detectable HCV RNA at end of treatment, which became undetectable at 12 weeks, post-treatment. 38 /38 (100%) patients without cirrhosis while 41/43 patients (95.3%) with compensated cirrhosis and 3/3 with decompensated cirrhosis achieved sustained virological response. Two (2.3%) patients had on-treatment virological failure. Four patients were lost to follow up.

Conclusion: Treatment with sofosbuvir and velpatasvir is effective and well tolerated in patients with chronic
hepatitis C, genotype 3.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

24-02-2021

How to Cite

Khan, A. Q., Mansoor, H., Fida, S., Saif, S., Iqbal, J., & Siddique, M. (2021). SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3. Pakistan Armed Forces Medical Journal, 71(1), 122–28. https://doi.org/10.51253/pafmj.v71i1.4339

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 > >>